A novel mRNA cancer vaccine helps reduce the chances of melanoma patients' tumors returning

Read the original at Toronto Star ↗
Cite

Neergaard, L. (2026, October 22). A novel mRNA cancer vaccine helps reduce the chances of melanoma patients' tumors returning. Toronto Star. https://www.thestar.com/news/world/a-novel-mrna-cancer-vaccine-helps-reduce-the-chances-of-melanoma-patients-tumors-returning/article_8e605465-f902-5f18-8209-5c5b35973f7b.html

Dated from the outlet's own feed. Check the original for its byline.

Toronto Star · collected 2026-10-22 · by Lauran Neergaard

Quick Summary

Moderna and Merck released results from a major study showing that an mRNA-based cancer vaccine called intismeran significantly reduces by 42% the risk of melanoma returning two years after surgery. The personalized vaccine, which targets unique gene mutations in each patient's tumor, was administered alongside standard post-surgery treatment to over 1,100 people with high-risk melanoma. At the end of the trial, 82% of patients receiving the vaccine remained cancer-free compared to 70% in the control group.
Written locally by qwen2.5:14b on 2026-10-23, using this article's own text rather than the other coverage of the same event (that is the story summary below).

AI analysis runs on qwen2.5:14b, locally

Story summary

A large clinical trial combining Moderna's mRNA cancer vaccine with Merck's immunotherapy drug Keytruda has shown a 42% reduction in the risk of melanoma recurrence or death over two years. The Phase 3 study, involving more than 1,100 patients, also revealed that the combination therapy reduced the likelihood of cancer spreading by 38%. This breakthrough marks a significant step forward for personalized oncology and could pave the way for similar treatments targeting other types of cancers. However, both Moderna and Merck saw their stock prices drop on Thursday after the trial results were leaked online, with Moderna shares falling over 17% and Merck's down about 1.8%. The study was led by Australian scientist Professor Georgina Long from the University of Sydney, highlighting potential global applications for personalized cancer vaccines in treating melanoma and possibly other cancers.

Written for “mRNA Cancer Vaccine For Melanoma” on 2026-10-23, grounded in this article and the 3 other(s) covering the same event.
Why this leaning score
This article does not take a side on a contested political question, so it has no leaning score. That is an answer rather than a gap: a match report or a rescue can be warmly or critically written without being left or right, and scoring it anyway is how approval of a subject gets recorded as a political position.
No political leaning scored for article 100600 · logged 2026-10-23

Story

📰 mRNA Cancer Vaccine For Melanoma
Health · 4 article(s) covering the same event. Compare every outlet's account →

Compared with similar articles

This article reads unscored and hedges 9% of its claims. Each row says how that neighbour differs.
The Independent · 0.91 cosine similarity
⚖️ leaning not scored 🔴 0% hedged 0 of 16 📰 publisher trust 59
“Both articles report on the same clinical trial results announced by Moderna and Merck on the same day, showing a 42% reduction in melanoma recurrence risk.”
TIME · 0.85 cosine similarity
⚖️ leaning not scored 🔴 11% hedged 3 of 28 📰 publisher trust 59
“Both articles report on the same study released by Moderna and Merck regarding a personalized cancer vaccine for melanoma patients, with identical results of reducing recurrence risk by 42%.”
Daily Mail
⚖️ leaning not scored 🔴 10% hedged 1 of 10 📰 publisher trust 64
“Both articles report on the release of results from a major study involving a new cancer vaccine by Moderna and Merck, which significantly reduced the risk of melanoma recurrence in patients.”
How this article was measured signals, leaning charts, publisher record, byline, topics and claims

Signals How these are calculated →

Claims extracted
35
sentences that state something as happening or true
Uncertain
9%
3 of 35 hedged ("reportedly", "may", "according to")
Leaning
not political
takes no side on a contested political question
Publisher signals
64/100
Toronto Star's corrections and hedging, across everything collected from it. Not a measure of accuracy.
Outlets on this story
4
Health
Same framing elsewhere
1
articles that frame the event the way this one does
Analyzed 2026-10-23 · how these are computed

How this is being covered How these are calculated →

Article leaning vs. publisher reliability
Source leaning vs. consistency

Publisher

Toronto Star · 9191 article(s) · 25 correction(s) detected
Running correction rate · 25 correction(s)
2026-10-07
Correction
2026-09-24
Correction

Who wrote this

Lauran Neergaard
3 article(s) here · 1 carrying a prediction
🔮 “It’s a big step forward for science, for oncology, because this vaccine will apply to many different cancers,” said Dr. Michael Atkins, deputy director of Georgetown University’s Lombardi Comprehensive Cancer Center.
🔮 The shot-averse could choose a nasal spray, FluMist, if they're ages 2 to 49 and meet other health criteria.
🔮 The shot-averse could choose a nasal spray, FluMist, if they’re ages 2 to 49 and meet other health criteria.
Also by Lauran Neergaard
Nothing else under this byline is closely related to this article, so these are simply their most recent.

Topics

Houston MD Anderson Cancer Center Merck Moderna WASHINGTON

Subjects

Merck ORG · 4× Moderna ORG · 4× Houston GPE · 2× Georgetown University’s ORG · 1× Hussein Tawbi PERSON · 1× Karen Knudsen PERSON · 1× MD Anderson Cancer Center ORG · 1× Michael Atkins PERSON · 1× WASHINGTON GPE · 1× the Parker Institute ORG · 1×

Narrative

Moderna and Merck had announced in August that the late-stage trial of intismeran was successful but the detailed results were set to be released Saturday at a meeting of the European Society of Medical Oncology in Madrid.
framing: assertive · carried by 1 article(s) · first seen 2026-10-23
🔮 “It’s a big step forward for science, for oncology, because this vaccine will apply to many different cancers,” said Dr. Michael Atkins, deputy director of Georgetown University’s Lombardi Comprehensive Cancer Center.

Claims (35 extracted, 3 hedged)

A first-of-its-kind cancer vaccine is significantly reducing the chances that melanoma patients’ tumors come back, according to results of a major study released Thursday by drugmakers Moderna and Merck. uncertain
tumors → reduce → Moderna
The vaccine was custom-brewed for each patient to match their tumor. asserted
vaccine → brew → tumor
Adding it to a standard post-surgery treatment reduced by 42% the risk of melanoma returning two years after surgery, according to the most advanced study to date of this new strategy for fighting cancer. uncertain
melanoma → add → cancer
“The field has been looking for a win and I think this one is a big one,” said Dr. Hussein Tawbi of MD Anderson Cancer Center in Houston, one of the researchers in the international study. asserted
Tawbi → look → study
The vaccine, called intismeran, is made with the same Nobel Prize-winning mRNA technology that was behind COVID-19 vaccines. asserted
that → call → vaccines
Experimental personalized cancer vaccines made with mRNA and some other approaches also are being tested against other types of cancer including lung, kidney and pancreatic. asserted
vaccines → make → lung
Experts not involved with the new study say its success bolsters the field. asserted
success → involve → field
“This is a new frontier,” said Karen Knudsen, CEO of the Parker Institute, which helps fund cancer immunotherapy research. asserted
which → say → research
“It’s a big step forward for science, for oncology, because this vaccine will apply to many different cancers,” said Dr. Michael Atkins, deputy director of Georgetown University’s Lombardi Comprehensive Cancer Center. asserted
Atkins → ’ → Center
Moderna and Merck had announced in August that the late-stage trial of intismeran was successful but the detailed results were set to be released Saturday at a meeting of the European Society of Medical Oncology in Madrid. asserted
results → announce → Madrid
Some of the data was leaked publicly late Thursday, prompting a full release ahead of the weekend’s scientific presentation. asserted
Some → leak → presentation
Most people think of vaccines as preventing an infection, like measles or whooping cough. asserted
people → think → measles
There are already two cancer-preventing vaccines, the HPV and hepatitis B shots that block infection from those tumor-causing viruses. asserted
that → be → viruses
And research is underway to prevent some types of inherited cancer such as Lynch syndrome-caused colorectal cancer. asserted
research → prevent → cancer
But a personalized vaccine designed to block surgically-removed cancer from returning is very different. asserted
vaccine → design → cancer
For the intismeran study, scientists hunted gene mutations unique to each patient’s tumor, mutations that create proteins which shouldn’t be in the body unless those cancer cells start to grow again. asserted
cells → hunt → body
The custom vaccine — nine doses given three weeks apart — teaches the patient’s immune system to watch out for and attack those so-called neoantigens. asserted
vaccine → give → neoantigens
How did it work? asserted
it → work → ?
The study included more than 1,100 people with high-risk melanoma that was surgically removed. asserted
that → include → melanoma
Everyone was given the standard follow-up therapy: Merck’s immunotherapy named Keytruda. asserted
Everyone → give → therapy
The participants were randomly assigned to also receive custom-brewed vaccine doses or a placebo. asserted
participants → assign → doses
Two years later, 82% of the people in the vaccine group were still living without a recurrence of their cancer compared to 70% who had gotten standard Keytruda alone. asserted
who → live → Keytruda
The trial is continuing to track participants’ longer-term outcomes. asserted
trial → continue → outcomes
In 2024, Tony Hout joined the vaccine trial at MD Anderson after seeking care for a spot on his ear that had been bleeding intermittently and wouldn’t fully heal. asserted
that → join → ear
Doctors recognized melanoma and during surgery discovered it had started to spread. asserted
it → recognize → surgery
“I want to make sure I’m doing everything I can to be here for my family,” said Hout, 62, who has since moved to Cayuga, Indiana, and travels back to Houston every few months for a study check-up. asserted
who → want → up
Scans this week showed he’s still cancer-free. asserted
he → show → ?
The vaccine’s side effects were mainly the sore arm, fatigue and other reactions typical of mRNA coronavirus vaccination, MD Anderson’s Tawbi said. asserted
Tawbi → say → vaccination
Moderna and Merck are talking with regulatory authorities about next steps for seeking approval of the vaccine. asserted
Moderna → talk → vaccine
The drugmakers aren’t discussing what such a cancer vaccine might cost. uncertain
vaccine → discuss → what
But Moderna President Stephen Hoge said the company’s special cancer vaccine manufacturing facility in Massachusetts is providing doses for thousands of people enrolled in multiple studies underway internationally. asserted
facility → say → studies
Hoge said it takes a few days to brew the vaccine but the whole process, starting with analyzing the tumor genetics to come up with what is essentially a recipe for each patient, can take roughly six weeks, sometimes more. asserted
what → say → weeks
Meanwhile, the melanoma patients had already started their standard Keytruda, a different kind of immunotherapy. asserted
patients → start → immunotherapy
Moderna shares dropped 18% Thursday after the study’s full results were made public, but they remained more than 200% higher than they were in late August before investors were first told of the initial results. asserted
investors → drop → results
The Associated Press’ health and science coverage receives financial support from the AP Fund for Journalism and private foundations. asserted
coverage → receive → Journalism
💬Give feedback
🕘History 🎫Support